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PHeart Rhythm Disorders
RS Duration Does Not Predict Occurrence
f Ventricular Tachyarrhythmias in Patients
ith Implanted Cardioverter-Defibrillators
lfred E. Buxton, MD, FACC,* Michael O. Sweeney, MD, FACC,† Mark S. Wathen, MD,‡
ark E. Josephson, MD, FACC,§ Mary F. Otterness, MS, Elaine Hogan-Miller, PHD, RN,
lice J. Stark, PHD, RN, Paul J. DeGroot, MS, for the PainFREE Rx II Investigators
rovidence, Rhode Island; Boston, Massachusetts; Nashville, Tennessee; and Minneapolis, Minnesota
OBJECTIVES The aim of this study was to determine whether QRS duration (QRSd) correlates with
occurrence of ventricular arrhythmia in patients with coronary disease (CAD) receiving
implantable cardioverter-defibrillators (ICDs).
BACKGROUND A QRSd measured on a standard electrocardiograph (ECG) correlates with total mortality
risk in CAD patients at high risk for sudden death; however, the relationship between QRSd
and risk of ventricular tachyarrhythmias (ventricular tachycardia/ventricular fibrillation
[VT/VF]) is unclear.
METHODS PainFREE Rx II was a randomized trial, comparing efficacy of antitachycardia pacing versus
shock therapy for VT/VF in patients receiving ICDs. We retrospectively correlated the QRSd
and specific ECG conduction abnormalities on the 12-lead ECG at study entry with
occurrence of VT/VF in 431 patients with CAD enrolled in the trial.
RESULTS The QRSd was120 ms in 291 of 431 (68%) patients. Left bundle branch block (LBBB) was
present in 65 patients, right bundle branch block (RBBB) in 48 patients, and nonspecific
intraventricular conduction delay (IVCD) was present in 124 patients. Over 12 months’
follow-up, VT/VF occurred in 95 (22%) patients (22% of patients with QRSd 120 ms vs.
23% of patients with QRSd 120 ms, p  NS). Patients with LBBB were less likely to
experience at least one VT/VF episode than patients with QRSd 120 ms. Patients with
RBBB and nonspecific IVCD did not differ from patients with narrow QRS complexes with
regard to occurrence of tachycardias.
CONCLUSIONS The QRSd and ECG conduction abnormalities are not useful to predict ICD benefit in
patients having the characteristics of our study population. The utility of QRSd to predict
VT/VF events in patients with CAD requires further prospective evaluation. (J Am Coll
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.03.060Cardiol 2005;46:310–6) © 2005 by the American College of Cardiology Foundation
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emplantable cardioverter-defibrillators (ICDs) reduce the
isk of sudden death and total mortality in patients who
ave survived spontaneous episodes of potentially lethal
entricular tachyarrhythmias (1). The ICDs reduce mortal-
See page 317
ty as well as risk of sudden death in some patients with
hronic coronary artery disease (CAD) that have never
xperienced symptomatic ventricular tachyarrhythmias (2–
). The results of these trials have led to increasing numbers
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005, accepted March 15, 2005.f patients that may benefit from ICD therapy. Although
CD therapy is highly effective, it is expensive and carries
ertain risks. Therefore, we must strive to identify charac-
eristics of patients most likely to benefit from this therapy
nd minimize the number of implants in patients that do
ot require this therapy.
Clearly, the risk of sudden death and total mortality is not
qual among all patients meeting the entry criteria of the
eported trials. Previous studies of patients with CAD have
dentified a number of factors carrying prognostic signifi-
ance in patients at risk for sudden death. Among the
actors related to prognosis are the presence of certain
lectrocardiographic (ECG) conduction abnormalities and
RS duration (QRSd) on the standard ECG (5). One
tudy suggested that patients with very wide QRS com-
lexes (150 ms) might derive greater survival benefit from
CD therapy than patients with narrow QRS complexes (4).
lthough duration of the QRS complex and the presence of
undle branch block are associated with poor prognosis in
ertain populations, there are no data showing a cause-and-
ffect relationship between electrocardiographic conduction
bnormalities and ventricular tachyarrhythmias. Hence, it is
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July 19, 2005:310–6 QRS Duration Versus Ventricular Arrhythmiaot clear whether basing decisions to implant ICDs on
RSd or conduction abnormalities will be useful clinically.
The purpose of the current study was to examine the
elationship between conduction abnormalities and QRSd
n the standard ECG and the spontaneous occurrence of
entricular tachyarrhythmias in patients receiving clinically
ndicated ICDs. We also sought to determine whether
atients receiving ICD implantation for primary prevention
ersus secondary prevention indications differed with regard
o the influence of QRSd or specific conduction abnormal-
ties on occurrence of tachyarrhythmias.
ETHODS
atient population. This analysis was performed on data
rom patients with CAD enrolled in the PainFREE Rx II
tudy (6). This was a randomized trial comparing empiric
ntitachycardia pacing (ATP) versus shocks as therapy for
pontaneous episodes of rapid ventricular tachyarrhythmias
n patients receiving ICDs. Patients receiving clinically
ndicated ICDs were eligible for participation in this trial if
hey did not have hypertrophic cardiomyopathy, Brugada,
r long QT syndromes. A total of 634 patients were
nrolled at 42 U.S. centers from January 2001 to March
002. Of these, 431 had CAD and a standard 12-lead ECG
uitable for analysis. Only these 431 patients were included
n the current analysis. Two hundred six (48%) of these
atients received ICDs for primary prevention of sudden
eath, and 225 received the ICD for secondary prevention.
target follow-up period of one year was incorporated into
he trial design. Patients were treated with ICDs from the
EM family of Medtronic ICDs. In 75% of cases, dual-
hamber ICDs were implanted. The ICDs were pro-
rammed to uniform VT detection criteria at the time of
mplantation. Three detection zones were utilized: a “slow
T zone” (cycle length cut-off 320 to 360 ms), a “fast VT
one” (320 to 240 ms), and a “VF zone” (cycle length
240 ms). For Fast VT and VF, the number of intervals to
etection was programmed to 18 out of 24 intervals,
hereas slow VT required 16 consecutive intervals to detect.
he ICD has the capability to store data for the last 150
Abbreviations and Acronyms
ATP  antitachycardia pacing
CAD  coronary artery disease
ECG  electrocardiograph/electrocardiographic
EF  ejection fraction
ICD  implantable cardioverter-defibrillator
LBBB  left bundle branch block
MI  myocardial infarction
MUSTT  Multicenter Unsustained Tachycardia Trial
QRSd  QRS duration
RBBB  right bundle branch block
VF  ventricular fibrillation
VT  ventricular tachycardiapisodes of ventricular fibrillation (VF) and/or ventricular dachycardia (VT). Each episode stored can contain an
lectrogram strip up to twenty-five seconds in duration.
Each participant in this trial provided written informed
onsent according to the institutional committee on human
esearch at each study site. The institutional review board at
very site approved the study protocol.
CG analysis. Standard 12-lead ECGs were collected
rom all patients upon entry to the trial. The ECGs were
nterpreted by a core laboratory that classified the presence
f left bundle branch block (LBBB), right bundle branch
lock (RBBB), and nonspecific intraventricular conduction
elay, as well as measuring the QRSd, using standard
riteria (7). The core laboratory physicians scoring the
CGs had no information regarding indication for ICD
primary vs. secondary prevention) or occurrence of tachy-
rrhythmia episodes.
The QRSd was measured from the earliest onset of the
RS complex to the point where the QRS complex
eturned to baseline. The lead with the longest QRSd was
sed for this measurement.
efinitions. PRIMARY PREVENTION INDICATION FOR ICD.
his group was composed primarily of: 1) patients with
AD, left ventricular ejection fraction (EF) 0.40, spon-
aneous nonsustained ventricular tachycardia (NSVT), and
nducible sustained VT; or 2) patients with CAD and EF
0.30. Excluded from this group were: 1) patients with a
istory of spontaneous sustained VT or VF, as well as 2)
atients with unexplained syncope in whom sustained VT
ould be induced.
ECONDARY PREVENTION INDICATION FOR ICD. Secondary
revention indication for ICD was defined as: 1) spontaneous
F or cardiac arrest without transient or reversible cause; 2)
pontaneous sustained VT; or 3) syncope of unknown etiology
nd sustained VT or VF inducible by programmed
timulation.
BBB. Left bundle branch block was defined by a QRSd
120 ms, delayed onset of the intrinsicoid deflection in
eads I, V5, V6 50 ms, the presence of a broad monopha-
ic, often notched R-wave in leads I, V5 and V6, with rS or
S complexes in lead V1 and V2, and ST-T-wave vectors
pposite in direction to the major QRS vector (7).
BBB. Right bundle branch block was defined by a QRSd
120 ms, in association with the presence of rsR=, or rSR=
omplexes in V1 or V2, delayed onset of the intrinsicoid
eflection in V1 and V2 more than 50 ms, and wide, slurred
waves in leads I, V5, and V6. The ST-T-wave vectors are
pposite in direction to the major QRS vector (7).
NTRAVENTRICULAR CONDUCTION DELAY. Intraventricular
onduction delay was defined as QRSd 110 ms with
orphology different than left bundle branch block or right
undle branch block (7).
UDDEN CARDIAC DEATH. A sudden cardiac death was a
eath within 1 h after onset of acute symptoms, including
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QRS Duration Versus Ventricular Arrhythmia July 19, 2005:310–6nwitnessed death that was unexpected and without other
pparent cause or death during sleep.
ON-SUDDEN CARDIAC DEATH. Non-sudden cardiac death
as defined as all cardiac deaths not classified as sudden
eaths, including cardiac deaths of hospitalized patients on
notropic support.
ON-CARDIAC DEATH. Non-cardiac deaths were deaths not
lassified as cardiac.
NKNOWN. If insufficient information was available, the
lassification is “unknown.”
nalysis of end points. An expert panel analyzed all
vailable stored electrograms of VT/VF episodes to verify
he ventricular origin of tachycardias. The expert panel
lassifying electrograms was blinded to the results of the
2-lead ECG analysis. We analyzed the relation of QRSd
o events in two ways. The primary analysis was performed
ichotomizing patients on the basis of QRSd 120 ms
ersus 120 ms. We also analyzed results using the stan-
ard medical definition of QRSd120 ms versus120 ms.
All deaths were reviewed by an Adverse Events Adjudi-
ation Committee, composed of three members blinded to
andomization group, to the study objectives, and to QRSd.
he committee was provided with the classification of death
s specified by the investigator, the patient’s history, and the
hysician’s dictated death summary. Deaths were classified
s sudden, non-sudden cardiac, non-cardiac, or unknown.
tatistical analysis. Continuous variables are summarized
s median, 25th, and 75th percentiles, and are compared
sing the Wilcoxon rank sum test. Dichotomous variables
re described by numbers and percentages and are compared
sing the Fisher exact test. All tests were performed at the
% type I error level; however, the Hochberg method was
sed to adjust the testing levels for demographic compari-
able 1. Patient Characteristics
Variable
Secondary
Prevention
(n  225)
Primary
Prevention
(n  206)
ge (yrs) 69 (61,75) 71 (64,77)
ale 175 (78) 174 (84)
I within 6 months 51 (23) 31 (15)
I 6 months 144 (64) 126 (61)
Anterior MI 87 (39) 67 (33)
Inferior MI 107 (48) 93 (45)
ateral MI 34 (15) 23 (11)
ypertension 144 (64) 118 (57)
rior CABG 116 (52) 123 (60)
rior PCI 66 (29) 53 (26)
F (%) 30 (25,40) 30 (20,35)
ollow-up duration (months) 12 (11,13) 12 (12,13)
haracteristics are presented for patients receiving implantable cardioverter-
efibrillators for secondary versus primary prevention indications (see text for
efinition). Data are presented as numbers (percent) for dichotomous variables, and as
edian (25th, 75th percentile) for continuous variables. There was no significant
ifference between the two groups with respect to any variable. These are not mutually
xclusive.
CABG  coronary artery bypass graft; EF  ejection fraction; MI  myocardial
nfarction; PCI  percutaneous coronary intervention. vons, in order to account for multiple comparisons (8).
ogistic regression was used to investigate differences in the
ikelihood of at least one episode. Kaplan-Meier survival
urves were constructed to illustrate time-to-event informa-
ion between dichotomized QRSd groups for ventricular
achyarrhythmia and death events. Log-rank p values are
eported in these cases.
ESULTS
haracteristics of patients enrolled are delineated in Table 1.
s expected, most patients had a history of myocardial infarc-
ion (MI), and in most cases, the MI had occurred more than
ix months prior to enrollment in this study. The characteris-
ics of patients who received ICDs for primary versus second-
ry prevention did not differ significantly. The median EF for
oth groups was 30%. The median duration of follow-up in
his study was 12 months for both patient groups.
able 2. Electrocardiographic Characteristics
Variable
Secondary
Prevention
(n  225)
Primary
Prevention
(n  206)
RS duration 120 ms 153 (68) 138 (67)
RS duration 120 ms 72 (32) 68 (33)
BBB 26 (12) 39 (19)
BBB 24 (11) 24 (12)
VCD 70 (31) 54 (26)
haracteristics are presented for patients receiving implantable cardioverter-
efibrillators for secondary versus primary prevention indications (see text for
efinition). Data are presented as numbers (percent). Values do not differ significantly
etween the two groups.
IVCD  nonspecific intraventricular conduction delay; LBBB  left bundle
ranch block; RBBB  right bundle branch block.
able 3. Patient Arrhythmia Characteristics by ICD Indications
ategories
Variable
Secondary
Prevention
(n  225)
Primary
Prevention
(n  206) p Value
ocumented spontaneous
arrhythmias
Sustained monomorphic VT 102 (45) 0 0.001*
Sustained polymorphic VT 10 (4) 0 0.01
Ventricular flutter 4 (2) 0 0.12
Ventricular fibrillation 44 (20) 0 0.001*
Torsades de Pointes 3 (1) 0 0.25
NSVT 54 (24) 180 (87) 0.001*
Atrial tachycardia 2 (1) 4 (2) 0.43
AV node re-entry 0 4 (2) 0.05
Atrial flutter 3 (1) 7 (3) 0.20
Atrial fibrillation 41 (18) 53 (26) 0.063
nduced arrhythmias
Sustained monomorphic VT 117 (52) 164 (80) 0.001*
Sustained polymorphic VT 13 (6) 24 (12) 0.038
Ventricular flutter 2 (1) 12 (6) 0.01
Ventricular fibrillation 34 (15) 15 (7) 0.014
NSVT 18 (8) 21 (10) 0.502
haracteristics are presented for patients receiving implantable cardioverter-
efibrillators (ICDs) for secondary versus primary prevention indications (see text for
efinition). Data are presented as numbers (percent). *Significant p values, because
esting criteria must be adjusted for multiple comparisons.AV  atrioventricular; NSVT  nonsustained ventricular tachycardia; VT 
entricular tachycardia.
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July 19, 2005:310–6 QRS Duration Versus Ventricular ArrhythmiaApproximately one-third of the patients had a QRSd
120 ms, regardless of the ICD indication (Table 2).
ikewise, the distribution of specific conduction abnormal-
ties was similar for primary and secondary prevention
atients (Table 2).
The characteristics of spontaneous and induced arrhyth-
ias are presented in Table 3. A substantial minority of
atients had a history of atrial tachyarrhythmias. Spontane-
us NSVT was documented more frequently in the primary
revention patients. Sustained monomorphic VT was in-
uced more frequently in primary prevention patients.
During follow-up, a total of 95 patients experienced at
east one ICD therapy in response to a ventricular tachyar-
hythmia. Twenty-three of the 138 (17%) primary preven-
ion patients with a QRSd 120 ms experienced an
pisode. In comparison, 13 of the 68 (19%) primary pre-
ention patients with a QRSd 120 ms experienced an
pisode (p NS). Forty of 153 (26%) secondary prevention
atients with a QRSd120 ms experienced an episode, and
able 4. Predictive Value of QRS Duration Using 10-ms Cutoffs
QRS Cutoff
(ms)
False
Positives (n)
True
Positives (n)
True
Negatives (n) Neg
80 303 90 33
90 271 82 65
100 198 54 138
110 168 46 168
120 108 32 228
130 92 26 244
140 56 18 280
150 43 17 293
160 13 8 323
170 12 6 324
180 2 2 334
igure 1. Time to ventricular tachycardia/ventricular fibrillation by QRS d
value was 0.85. Solid line  QRSd 120 ms group; broken line  Q190 1 1 335 949 of 72 (26%) secondary prevention patients with a QRSd
120 ms experienced an episode (p  NS). Overall
primary and secondary prevention patients grouped to-
ether), the odds of experiencing an episode in patients
hose QRSd was 120 ms was 1.072 times that for
atients having a QRSd 120 ms (95% confidence limits
.66 to 1.74; p  NS). Similar results were obtained when
e compared patients with QRSd 120 ms versus 120
s. Furthermore, we found no difference in time to first
entricular tachyarrhythmic event between QRSd groups
Fig. 1).
Because treatment with ATP occurs with less time delay
han shock therapy, it is possible that some episodes of
achycardia treated with ATP as initial therapy could
epresent “false positive episodes” that would have termi-
ated spontaneously after charging, before shock delivery.
herefore, we performed a similar analysis, counting only
pisodes of ICD discharge for the 220 patients randomized
o shock as initial therapy for fast VT, excluding slow VT
s (n) Sensitivity (%) Specificity (%)
Positive
Predictive
Value (%)
Negative
Predictive
Value (%)
95 10 23 87
86 19 23 83
57 41 21 77
48 50 21 77
34 68 23 78
27 73 22 78
19 83 24 78
18 87 28 79
8 96 38 79
6 96 33 78
2 99 50 78
n (QRSd) in days. There were 95 patients with events, and the log-rank
120 ms group.False
ative
5
13
41
49
63
69
77
78
87
89
931 99 50 78
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QRS Duration Versus Ventricular Arrhythmia July 19, 2005:310–6cycle length 320 ms) episodes. This analysis provided
imilar results. Overall, 11 (15%) of 75 patients with a
RSd 120 ms versus 17 (12%) of 145 patients having
RSd120 ms experienced an episode of tachycardia (p
S; odds ratio 1.29 [95% confidence limits 0.57 to 2.93]).
We also analyzed the relation between QRSd and tachy-
ardia episodes, examining a variety of QRSd cutoffs. We
nalyzed the sensitivity and specificity of QRSd, ranging
rom 80 to 190 ms in 10-ms intervals (Table 4). No QRSd
utoff yielded a clinically useful combination of sensitivity or
pecificity. Similar results were obtained when we examined
roups of patients receiving ICDs for primary or secondary
revention individually.
We then evaluated the relation between QRSd and
requency of VT/VF episodes for patients who experienced
t least one episode of VT/VF during the follow-up period
Table 5). The density of recorded tachycardia episodes in
atients with one or more episodes was not related to QRSd
or primary or secondary prevention patients using the
120 and 120 ms dichotomization.
We also evaluated the relation between specific conduc-
ion abnormalities and the occurrence of VT/VF (Table 6).
atients with LBBB were significantly less likely than
atients with QRSd 120 ms to experience at least one
achycardia episode. This was not observed in comparisons
f patients with RBBB or patients with IVCD and patients
ith narrow QRS. Among patients experiencing at least one
achyarrhythmia episode, we found no evidence of a differ-
nce in episode density.
We analyzed the relation between mortality and QRSd;
ignificantly more patients died in the QRSd 120 ms
roup than in the QRSd 120 group, 15% (21 of 140)
ersus 9% (25 of 291) (p  0.047). When examining the
Table 5. Density of Tachycardia Episodes as R
ICD Indication
Primary prevention (n  206, 36 patients with episo
Secondary prevention (n  225, 59 patients with ep
*None of the differences were significant. †Statistics are base
of episodes recorded over the median follow-up of 12 mont
ICD  implantable cardioverter-defibrillator.
able 6. Relation of Specific Conduction Abnormalities to Densi
LBBB
(n  65)
QRSd <
(n  2
atients with VT
n (%) 6 (9%) 50 (23
p value† 0.02
pisode density (mean  SD)‡ 5.0  8.4 9.9 
p values represent the comparison of those with LBBB or RBBB versus those with
s. †Groups are compared based on the proportion of patients with at least one appr
t least one episode. The number of patients with at least one episode is found in the se
nd no significant difference was found.
VT  ventricular tachycardia; other abbreviations as in Table 2.ime to the event of either a ventricular tachyarrhythmia or
ll-cause death, however, no difference was found between
he two groups (pNS). Figure 2 depicts the results of this
nalysis. Table 7 details the causes of deaths for the two
RSd groups. The population experienced two sudden
ardiac deaths and three deaths of unknown cause. In fact,
nly three of these five patients died without experiencing a
ecorded ventricular tachyarrhythmia. Thus, the Kaplan-
eier survival curve for time to the event of either ventric-
lar tachyarrhythmia or SCD or death from unknown
auses would be similar to Figure 1.
ISCUSSION
he major finding of this study is that QRSd does not
redict occurrence of VT/VF resulting in ICD therapies.
he results were similar for patients who received ICDs for
oth primary as well as secondary prevention indications.
his observation was true whether QRSd was dichotomized
t 120 ms or was dichotomized at other cutoffs. Further-
ore, whereas the presence of RBBB and IVCD was not
ssociated with the occurrence of at least one VT/VF
pisode, patients with LBBB were less likely to experience
t least one VT/VF episode than patients with narrow QRS
omplexes. Among patients with at least one episode,
owever, we did not detect a difference in episode density
etween those with LBBB and those with narrow QRS
omplexes. This may have been due to small sample size.
We do not believe these findings to be surprising. We are
ot aware of data that show any direct link between
lectrocardiographic conduction abnormalities and the de-
elopment of VT/VF after MI. The presence of conduction
bnormalities is not associated with an increased chance of
d to QRS Duration*†
QRS
Duration
Number of Episodes‡
Median (25th, 75th Percentile)
120 ms 2 (1,6)
20 ms 1 (1,5)
) 120 ms 2 (1,6.5)
20 ms 3 (2,15)
ata only from patients with at least one episode. ‡Numbers
VT*
Attribute
s RBBB
(n  47)
IVCD
(n  123)
QRSd <110 ms
(n  179)
10 (21%) 35 (28%) 41 (23%)
NS NS
2.7  2.6 8.6  12.0 11.0  19.7
120 ms, or patients with IVCD versus those with QRS duration (QRSd) 110
ly detected spontaneous episode. ‡Episode density is only reported for patients with
row of the table. Because of small sample size, only the IVCD comparison was tested,elate
des)
isodes
d on dty of
120 m
19)
%)
18.3
QRSd
opriate
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July 19, 2005:310–6 QRS Duration Versus Ventricular Arrhythmiaaving inducible sustained VT in patients without prior
pontaneous sustained VT (5; The MUSTT Investigators,
npublished data, April 2004). Although patients who
xperience large MI are more likely to develop an ECG
onduction abnormality than those with lesser degrees of
yocardial involvement, in some cases, bundle branch block
ay antedate infarction and bear no relation to CAD. In
eneral, patients who develop bundle branch block as a
omplication of infarction have larger areas of infarction and
ncreased mortality. Furthermore, LBBB is unlikely to
esult from anterior MI and may be more likely to reflect the
resence of left ventricular hypertrophy. In the MUSTT
tudy (5), patients with LBBB or IVCD (but not RBBB)
ad a lower ejection fraction and a higher prevalence of
eart failure than patients without these abnormalities. The
oronary Artery Surgery Study (CASS) (9) investigators
bserved that LBBB, but not RBBB, was associated with
ncreased mortality. The MUSTT study (5) also found
atients with LBBB or IVCD, but not RBBB, to have
ncreased total mortality. In addition, the risk of arrhythmic
eath or cardiac arrest was increased in patients with LBBB
r IVCD. The increase in total mortality associated with
BBB or IVCD, however, outweighed the increase in
rrhythmic death risk, suggesting a lack of a cause-and-
ffect relation between conduction abnormalities and death.
his, in turn, would suggest that basing ICD therapy on the
resence of ECG conduction abnormalities is not likely to
e a very cost-effective way to reduce mortality of post-
nfarction patients.
igure 2. Time to ventricular tachycardia/ventricular fibrillation or all-caus
og-rank p value was 0.20. Solid line  QRSd 120 ms group; broken
Table 7. Relation of QRS Duration to Mode o
QRS Duration
Sudden Cardiac
Death C
120 ms 0
120 ms 2Recent studies have demonstrated a relation between
BBB and left ventricular dyssynchrony, potentially con-
ributing to development of heart failure (10,11). It seems
ikely that this effect may be at least partly responsible for
he increased mortality associated with certain conduction
bnormalities in patients with left ventricular dysfunction.
lthough these abnormalities seem likely to contribute to
ortality, there is no evidence, however, that they relate
pecifically to deaths that result from VT/VF.
tudy limitations. The PainFREE Rx II study, upon
hich this analysis is based, was not designed primarily to
nswer the question of whether electrocardiographic con-
uction abnormalities are causally related to the occurrence
f ventricular arrhythmias. Therefore, our observations are
ubject to the limitations of all substudies and cannot be
aken as proof that there is no relation between conduction
bnormalities and arrhythmia occurrence. The median
ollow-up of 12 months in this trial is relatively short.
herefore, it is possible that if patients were followed for
onger periods, different results might have been obtained.
inally, it must be acknowledged that the total number of
atients with specific conduction abnormalities in our study
as relatively small, thereby limiting the statistical power of
he comparisons.
It is likely that some patient populations with CAD and
ide QRS complexes (such as patients with advanced
ymptomatic heart failure who are candidates for bi-
entricular pacing ICDs) have different mortality risks than
ur study population. If one asked whether QRSd could
h by QRS duration (QRSd). There were 129 patients with events, and the
QRSd 120 ms group.
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rom a biventricular ICD rather than a biventricular pace-
aker) in a patient population with advanced CHF, it is
ossible that different results would be obtained. Today,
owever, candidates for biventricular devices are identified
rimarily by the presence of wide QRS complexes, so this
uestion would be difficult or impossible to answer.
onclusions. There is no relation between QRSd and
T/VF occurrence in patients with CAD who receive ICDs
or primary or secondary prevention of sudden death.
urthermore, with the exception of a modest difference in
he proportion of patients experiencing at least one tachy-
ardia episode between patients with LBBB and those with
arrow QRS, there was no relation between the occurrence
f tachyarrhythmias and specific conduction abnormalities.
hus, there seems to be little basis to recommend using
RSd or specific conduction abnormalities to base decisions
egarding utilization of ICD therapy in patients with the
haracteristics of the study population.
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